Business
VALEO PHARMA REPORTS RECORD QUARTERLY REVENUES FOR THE FIRST QUARTER 2023
VALEO PHARMA REPORTS RECORD QUARTERLY REVENUES FOR THE FIRST QUARTER 2023.
About this update from Valeo Pharma Inc.
[{"type":"text","content":"\n\n\n\nVALEO PHARMA REPORTS RECORD QUARTERLY REVENUES FOR THE FIRST QUARTER 2023\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nVALEO PHARMA REPORTS RECORD QUARTERLY REVENUES FOR THE FIRST QUARTER 2023\nCanada NewsWire\nMONTREAL, March 15, 2023\n\n\n\nFifth consecutive quarter of revenue growth at $13.2 million in Q1-23, up 210% over Q1-22Fifth consecutive quarter of adjusted gross profit increase at $4.2 million, up 178% over Q1-22Fifth consecutive quarter of adjusted EBITDA loss reduction at $2.2 million, a 51% improvement over Q1-22Physicians prescribing Enerzair and Atectura reached 1,583 at the end of Q1-23, representing 39% growth from the prior quarter and a 799% increase year-over-yearTotal annual Enerzair and Atectura prescriptions reached 34,000 at the end of Q1-23, up 41% sequentially and 1917% year-over-year.MONTREAL, March 15, 2023 /CNW/ - Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (\"Valeo\" or the \"Company\"), a Canadian pharmaceutical company, today reported its financial results for the first quarter ended January 31, 2023.\n\n \n \n \n \n \n \n\n \nFirst quarter 2023 Results & Highlights:Record quarterly revenues of $13.2 million in Q1-23, compared to $4.2 million in Q1-22, up 210%Record adjusted gross profit of $4.2 million in Q1-23 compared to $1.5 million in Q1-22, up 178%Q1-23 net loss of $6.2 million compared to $5.9 million in Q1-22Q1-23 adjusted EBITDA loss of $2.2 million compared to $4.5 million in Q1-22, A 51% reductionEnerzair and Atectura prescribing physicians reached 1,583 at the end of Q1-23, a 39% growth for the quarter and 799% increase year-over-yearTotal of 34,000 Enerzair and Atectura prescritions over the last 12-months at the end of Q1-23, up 41% sequentially and 1917% year-over-year\"Our core innovative products continue to gain market share in their respective therapeutic areas significantly contributing to our revenue and margin growth. Enerzair and Atectura, our asthma therapies, continue their rapid adoption with Enerzair now the leading drug in the fast-growing triple-active asthma market\", said Steve...